CLINICAL TRIALS PROFILE FOR REGULAR ILETIN II
✉ Email this page to a colleague
All Clinical Trials for REGULAR ILETIN II
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01068860 ↗ | To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies | Completed | Novartis | Phase 2 | 2010-02-01 | This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for REGULAR ILETIN II
Condition Name
Clinical Trial Locations for REGULAR ILETIN II
Trials by Country
Clinical Trial Progress for REGULAR ILETIN II
Clinical Trial Phase
Clinical Trial Sponsors for REGULAR ILETIN II
Sponsor Name